IM in the deltoid region≥15 yr 3-doses of 0.5 mL given at 0, 1 & 6 mth, 2nd dose can be administered between 1 & 2.5 mth & 3rd dose between 5 & 12 mth after 1st dose, if flexibility in vaccination schedule is necessary; 9-14 yr 2-doses of 0.5 mL, given between 5 & 13 mth after the 1st dose. If 2nd vaccine dose is administered before the 5th mth after the 1st dose, a 3rd dose should always be administered.
Do not administer intravascularly or intradermally. Anaphylactic event & syncope may occur. Postpone vaccination in patients w/ acute severe febrile illness. Thrombocytopenia or any coagulation disorder. Not intended for the prevention of progression of HPV-related lesions present at the time of vaccination or protection against all oncogenic HPV types. Not a substitute for regular cervical screening or against exposure to HPV & STD. Patients receiving immunosuppressive treatment. Postpone vaccination in women who are pregnant or trying to become pregnant until completion of pregnancy. Lactation.
Sign Out
